What is the clinical relevance of broader patient population studied in EMPA-KIDNEY?
25/01/2024 | Author: Boehringer Ingelheim
Document ID: PC-SG-102237
RELATED CONTENT
1:15
PEKP||Primary Care Physicians to Transform CKD Prognosis
1:25
PEKP||EMPA-KIDNEY: Benefits of Empagliflozin for A1 & A2
1:12
